Stocks · News reference
MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of $(1.06) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
8-K filing — MiNK Therapeutics, Inc. (INKT)
Filed: 2026-08-13 AccNo: 0001193125-26-347907 Size: 215 KB Item 2.02: Results of Operations and Financial Condition
MiNK Therapeutics Announces Launch Of Paid International Named-Patient Access Program For agenT-797 In Brazil With Orphan Drug Consulting